For important risk and disclaimer information, Click here
|
Richard Luftig | Managing Partner
|
|
|
|
(212) 418-1181
|
Overview
BioAro seeks growth capital for building out one of North America’s largest Genomics lab. For its Series A round, it is raising $8 million of equity and $4 million of debt
LEADERSHIP & ADVISORS
- CEO, Dr. Anmol Kapoor, is a serial entrepreneur, who is experienced running and scaling profitable entities in healthcare
- Growing team of doctors and scientists who are experts in their respective fields
- Advisory board in genetics/epigenetics/ageing
OPERATIONS & FINANCIAL SUMMARY
- 4 facilities across Canada and plans to expand in the US
- Strong supplier relationships to purchase key lab equipment at deep discounted prices
- $7m in sales and 20% margins
- $2m cash and debt-free
*** All values referenced here as at January 31, 2023 and in $CAD
TECH ASSETS
- Licensable software solutions to address unmet market needs
- Global patent portfolio
- Genomics labs & software capturing valuable patient data
- AI/Patient data will assist in creating new products
Opportunity
Industry insiders estimate that the future global genetic testing market will be as prominent as the blood testing market – certain countries have begun to offer whole genome sequencing as part of routine care
Management estimates that the global genetic market will grow at a CAGR of ~16% between 2022 and 2030
Sequencing genomes is a very manual, data intensive, and time-consuming process and the current BioAro labs only accommodate a limited number of tests in a year
Human genomic data is often sold to pharma companies by competitors and analyzed in labs outside of North America, exposing sensitive human data to vulnerabilities
As countries and organizations adopt genetic testing to prevent unhealthy aging and to increase life expectancy, a new norm in healthcare is possible – as an example, Dubai has set a goal to genetically map all citizens by 2030
Solution/Strategy
Management believes that BioAro’s upcoming licensable software will be a necessity for existing and future labs, as no real software solution exists today
New equipment purchased in 2023 should increase BioAro’s efficiencies while reducing cost per test, enabling a premium product at a more competitive rate
Preventative solutions such as BioAro’s preventative modules should reduce time to discovery and treatment, optimization of healthcare solutions, leading to lower healthcare costs and increased savings
BioAro allows clients to own their own data while managing, storing and retaining their genome data, as opposed to being sold or licensed to other healthcare entities
Management believes that BioAro will be one of the few labs globally that can provide the full gamma of sequencing services
Specific Risks
- Limited operational history on the new product lines
- Customer concentration risk
- Current operational cash flow all from one region – Canada.
- Identifying right talent to scale new business lines
- Management may not be able to execute as per projections
- Management has primarily operated in Canada, so other regions may have different regulations, customs and norms;
- Technology and/or products may not be adopted in a reasonable time frame
- Industry adoption rate may not be realized as forecasted
- Adoption rate of the products may not be realized as forecasted
- Larger competitors can outspend Company
- Larger public companies can acquire competitors and talent, and access large amounts of capital
- Key future intellectual property rights may not be granted
- The Company may not be able to monetize at the prices predicted on new project lines.
- Some of the Company’s current and potential competitors have longer operating histories and greater financial, technical, marketing and other resources
- Private securities are speculative, illiquid, and carry a high degree of risk – including the loss of the entire investment.